Bruker Co. (NASDAQ:BRKR) Receives $81.40 Consensus Target Price from Analysts

Shares of Bruker Co. (NASDAQ:BRKR) have been assigned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $81.40.

BRKR has been the subject of a number of research analyst reports. Jefferies Financial Group initiated coverage on shares of Bruker in a report on Monday, June 3rd. They issued a “buy” rating and a $85.00 price target for the company. Wells Fargo & Company assumed coverage on Bruker in a research note on Tuesday, August 27th. They set an “overweight” rating and a $78.00 price target on the stock. Citigroup dropped their price objective on Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Wednesday, July 10th. TD Cowen decreased their target price on Bruker from $74.00 to $72.00 and set a “hold” rating on the stock in a research report on Wednesday, August 7th. Finally, The Goldman Sachs Group lowered their target price on Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a report on Tuesday, July 9th.

Institutional Investors Weigh In On Bruker

Several hedge funds have recently modified their holdings of the company. Centaurus Financial Inc. purchased a new position in shares of Bruker during the 2nd quarter worth $291,000. Sanctuary Advisors LLC purchased a new stake in Bruker in the 2nd quarter valued at about $296,000. Gordian Capital Singapore Pte Ltd acquired a new position in shares of Bruker during the 2nd quarter valued at about $52,000. Maven Securities LTD lifted its holdings in shares of Bruker by 400.0% during the 2nd quarter. Maven Securities LTD now owns 20,000 shares of the medical research company’s stock worth $1,276,000 after acquiring an additional 16,000 shares during the period. Finally, Aristides Capital LLC acquired a new stake in shares of Bruker in the second quarter worth approximately $222,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Stock Down 0.6 %

Shares of Bruker stock opened at $67.16 on Thursday. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18. Bruker has a 52-week low of $53.79 and a 52-week high of $94.86. The company has a market capitalization of $9.76 billion, a P/E ratio of 24.42, a P/E/G ratio of 2.31 and a beta of 1.18. The company has a 50 day moving average of $64.64 and a 200 day moving average of $72.46.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.52. The company had revenue of $800.70 million for the quarter, compared to analysts’ expectations of $799.44 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. Bruker’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period last year, the firm earned $0.50 earnings per share. As a group, research analysts forecast that Bruker will post 2.61 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Monday, September 2nd were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.30%. The ex-dividend date was Friday, August 30th. Bruker’s payout ratio is 7.27%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.